Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT05531526

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 Over 52 Weeks in Participants With Early Alzheimer's Disease (Polaris-AD)

Sponsor: AriBio Co., Ltd.

Conditions Alzheimer Disease

Interventions AR1001 Placebo

Updated 27 times since 2022 Last updated: Sep 29, 2025 Started: Dec 23, 2022 Primary completion: May 31, 2026 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Alzheimer Disease and is currently ongoing. AriBio Co., Ltd. leads this study, which shows 27 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

27 versions recorded

Nov 2025 — Present [monthly]

Active Not Recruiting PHASE3
Sep 2025 — Nov 2025 [monthly]

Active Not Recruiting PHASE3
Aug 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE3
May 2025 — Aug 2025 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Apr 2025 — May 2025 [monthly]

Recruiting PHASE3

▶ Show 22 earlier versions

Mar 2025 — Apr 2025 [monthly]

Recruiting PHASE3
Nov 2024 — Mar 2025 [monthly]

Recruiting PHASE3
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE3
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE3
Apr 2024 — Jun 2024 [monthly]

Recruiting PHASE3
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE3
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE3
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE3
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE3
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE3
Sep 2023 — Nov 2023 [monthly]

Recruiting PHASE3
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE3
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE3
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE3
May 2023 — Jun 2023 [monthly]

Recruiting PHASE3
Apr 2023 — May 2023 [monthly]

Recruiting PHASE3
Feb 2023 — Apr 2023 [monthly]

Recruiting PHASE3
Jan 2023 — Feb 2023 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Nov 2022 — Jan 2023 [monthly]

Not Yet Recruiting PHASE3
Sep 2022 — Nov 2022 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AriBio Co., Ltd.

Data source: AriBio Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's-Hertogenbosch, Netherlands , Aachen, Germany , Amherst, United States , Amsterdam, Netherlands , Ancona, Italy , Apopka, United States , Atlanta, United States , Bad Homburg, Germany , Barcelona, Spain , Beaumont, United States and 142 more locations